Despite losing patent protection for its blockbuster drug, Singulair, over the summer, pharma giant Merck's (NYSE: MRK) shares have appreciated 18% year to date, and the company has a slew of therapeutics in development. In addition, while some of the biggest players in the health care space -- including Pfizer (NYSE: PFE) and Abbott (NYSE: ABT) -- are spinning-out businesses, Merck doesn't look like it will be following suit.

In the following video, health care analysts Max Macaluso and Brenton Flynn discuss Merck's current strategy and give a helpful overview of the company's main growth drivers.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.